Advertisement
YOU ARE HERE: LAT HomeCollections

CALIFORNIA / News and Insight on Business in the Golden
State

Spotlight: Xoma Reports Encouraging Results in Trial of Drug

September 25, 1997

Xoma Corp. said its Neuprex drug shows no safety problems, according to an analysis of its ongoing trial in patients with a rare and often fatal childhood disease. Berkeley-based Xoma said the results mean it will continue developing Neuprex. The drug is used in pediatric patients with severe meningococcemia, which strikes when the bacteria responsible for the more common meningitis disease invade a patient's bloodstream. Xoma shares fell 6 cents to close at $7.75 on Nasdaq.

Advertisement
Los Angeles Times Articles
|
|
|